Nama's AI scorecard currently rates Xeris Biopharma Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is XERS's P/E ratio?

Xeris Biopharma trades at a trailing price-to-earnings ratio of 126.7.

When does XERS report earnings?

Xeris Biopharma's next scheduled report is on Mar 4, 2027. Analysts expect EPS of $0.07.

What is the XERS price target?

The median analyst price target from 7 analysts is $12.00, with a range of $8.00 – $18.00.

Is XERS Shariah compliant?

Nama's AAOIFI-style screen reads Xeris Biopharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Xeris Biopharma (XERS)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Xeris Biopharma (XERS) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $2.77B, a trailing price-to-earnings ratio of 126.7 and a free-cash-flow yield of 1.1%. Over the most recent reported fiscal year, revenue grew 43.7%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +31.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-0.1%

How far the last close sits under the highest price of the past five years.

Market cap	$2.77B
Trailing P/E	126.7
Price / book	—
Price / sales	8.3
FCF yield	1.1%
Dividend yield	—
Gross margin	86.6%
Operating margin	10.9%
Net margin	-5.1%
Revenue growth (YoY)	+43.7%
Revenue growth (3-yr annual)	+38.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

XERS earnings

Next report: Mar 4, 2027 (Q4 2026, EPS estimate $0.07). Beat the EPS estimate in 3 of 3 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.06	$0.03	+100.0%	—
Q1 2026	May 7, 2026	$0.01	—	—	$83.13M
Q4 2025	Mar 2, 2026	$0.06	$0.05	+20.0%	$85.81M
Q2 2025	Aug 7, 2025	-$0.01	-$0.03	+66.7%	$71.54M

XERS analyst price target

Median target $12.00 from 7 analysts, ranging $8.00 – $18.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live XERS data on Nama Insights →

XERS FAQ

Is XERS a buy?: Nama's AI scorecard currently rates Xeris Biopharma Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is XERS's P/E ratio?: Xeris Biopharma trades at a trailing price-to-earnings ratio of 126.7.
When does XERS report earnings?: Xeris Biopharma's next scheduled report is on Mar 4, 2027. Analysts expect EPS of $0.07.
What is the XERS price target?: The median analyst price target from 7 analysts is $12.00, with a range of $8.00 – $18.00.
Is XERS Shariah compliant?: Nama's AAOIFI-style screen reads Xeris Biopharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.